Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181404 | 0.95 | KLKB1 (0.40) | KLKB1SMN1; SMN2ATML3MBTL1MAPT | |
| SCHEMBL8978679 | 0.89 | SMN1; SMN2 (0.34) | SMN1; SMN2ATML3MBTL1MAPTMEN1 | |
| SCHEMBL10102261 | 0.85 | MAPT (0.36) | SMN1; SMN2ATML3MBTL1MAPTTDP1 | |
| SCHEMBL8978531 | 0.85 | SMN1; SMN2 (0.36) | SMN1; SMN2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL10102253 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2ATML3MBTL1MAPTMEN1 | |
| SCHEMBL13464551 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2ATML3MBTL1MAPTMEN1 | |
| SCHEMBL7001887 | 0.84 | EGFR (0.41) | SMN1; SMN2ATML3MBTL1MEN1KMT2A | |
| SCHEMBL10106951 | 0.83 | ATM (0.39) | SMN1; SMN2ATML3MBTL1MAPTMEN1 | |
| SCHEMBL7501188 | 0.83 | SMN1; SMN2 (0.34) | SMN1; SMN2MAPTMEN1KMT2ANR4A2 | |
| SCHEMBL10102251 | 0.83 | SMN1; SMN2 (0.37) | SMN1; SMN2ATML3MBTL1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8147726-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20110062396-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110062396-A1 | CHROMENE COMPOUND | CDYL, NR0B1, NR1H2 | KLKB1 1709/4885SMN1; SMN2 2922/4885ATM 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.